GlassScriptPhysician profile
Kamran A Qureshi
NPI 1326156472
$3,680.01
in general payments reported to CMS, 2019-2025
29 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.70 · 2022: $15.04 · 2023: $2,658 · 2024: $395 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,148 · Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,148.00 |
| Food and Beverage | $1,446.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,253.62 | 2023-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $129.35 | 2022-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $116.61 | 2023-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $80.84 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $78.11 | 2019-2023 | Verquvo, Belsomra |
| Glaxosmithkline, LLC. | $73.88 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Corcept Therapeutics | $71.23 | 2023 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.47 | 2023-2025 | Xifaxan |
| Novo Nordisk INC | $64.34 | 2024-2025 | Ozempic, Rybelsus |
| Acella Pharmaceuticals, LLC | $60.29 | 2024-2025 | NP Thyroid 60 |
| Exact Sciences Corporation | $58.43 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $55.49 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $55.41 | 2023-2024 | Horizant, Horizant |
| Amgen INC. | $54.50 | 2023-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $50.26 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.68 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.81 | 2023 | Jardiance, Tradjenta |
| Revance Therapeutics, INC. | $42.49 | 2025 | Daxxify |
| Hologic Sales and Service, LLC | $37.52 | 2023 | Aptima |
| Xeris Pharmaceuticals, INC. | $37.45 | 2023-2025 | Gvoke Hypopen |
| Shield Therapeutics INC | $28.68 | 2024 | |
| Dexcom, INC. | $28.33 | 2025 | Dexcom G6 Transmitter |
| Tolmar, INC. | $24.85 | 2025 | Jatenzo |
| Eisai INC. | $24.41 | 2025 | |
| Edwards Lifesciences Corporation | $20.97 | 2024 | Sapien 3 Ultra Resilia |
| Sumitomo Pharma America, INC. | $20.20 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $20.04 | 2019 | |
| Abbvie INC. | $19.71 | 2024 | |
| Esperion Therapeutics, INC. | $18.04 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.